Top 15 Cancer Stories of 2014

Slideshow

In this slide show we present some of the top cancer stories of 2014, including a newly discovered gene that confers a high-risk of breast cancer and the impressive survival improvement with the addition of docetaxel to ADT in newly diagnosed metastatic prostate cancer.

slideshow image

A germline loss-of-function mutation in the PALB2 gene was previously linked to breast cancer, but the lifetime risk of a breast cancer diagnosis for those with the mutation was previously unknown. Now researchers have shown that patients with mutations in PALB2 have a lifetime risk of breast cancer similar to BRCA2 mutation carriers.

Recent Videos
Standardized Toxicity Grading: Institutional Protocols for CRS and ICANS
Standardized Toxicity Grading: Institutional Protocols for CRS and ICANS
Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging
Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging
Differential Toxicity Profile: Tarlatamab vs Traditional Cytotoxic Therapies
Differential Toxicity Profile: Tarlatamab vs Traditional Cytotoxic Therapies
Epcoritamab Demonstrates Complete Responses at 2 Years in R/R LBCL
Epcoritamab Demonstrates Complete Responses at 2 Years in R/R LBCL
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
IMNN-001 May Show Enhanced Benefit in HRD-Positive Ovarian Cancer Subgroup
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
Unique Properties of ISB 2001 May Offer Benefits in R/R Multiple Myeloma
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Gene Assay Can Guide Chemo Strategies in Older Breast Cancer Population
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Targeted Tool May Optimize Infusion Therapy Delivery in Breast Cancer
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Pivotal Presentations That May Shape the Breast Cancer Standard of Care
The Role of Molecular Testing in Ovarian Cancer Care
The Role of Molecular Testing in Ovarian Cancer Care
Related Content
Data from DeLLphi-304 support tarlatamab as a preferable second-line therapy for patients with small cell lung cancer.

Second-Line Tarlatamab Improves PFS, OS in Small Cell Lung Cancer

Chris Ryan
June 5th 2025
Article

Data from DeLLphi-304 support tarlatamab as a preferable second-line therapy for patients with small cell lung cancer.

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

High Response Rates Seen with Fruquintinib Combo in HER2– Advanced Gastric/GEJ Cancer

High Response Rates Seen with Fruquintinib Combo in HER2– Advanced Gastric/GEJ Cancer

Kyle Doherty
June 4th 2025
Article

Fruquintinib plus chemotherapy and a PD-1 inhibitor elicited an ORR of 80.0% with all partial responses in patients with treatment-naïve gastric/GEJ cancer.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

The DREAM program led by Ankit Bharat, MD, MBBS, FACS, allowed Cornelia Tischmacher to receive a double lung transplant for her stage IV lung cancer.

An International Search for Lung Cancer Treatment Leads to Double Lung Transplant

Roman Fabbricatore
June 4th 2025
Article

The DREAM program led by Ankit Bharat, MD, MBBS, FACS, allowed Cornelia Tischmacher to receive a double lung transplant for her stage IV lung cancer.

Investigators of the OVATION-2 trial assessed IMNN-001, a novel IL-2 gene therapy, in patients with newly diagnosed epithelial ovarian cancer.

PFS, OS Numerically Improve Via IMNN-001 Combo in Epithelial Ovarian Cancer

Chris Ryan
June 4th 2025
Article

Investigators of the OVATION-2 trial assessed IMNN-001, a novel IL-2 gene therapy, in patients with newly diagnosed epithelial ovarian cancer.